Pharmacogenomic test that predicts response to β-agonists in adults with asthma is cost effective.

View Abstract

BACKGROUND

Pharmacogenomic tests that predict which asthma patients are likely to respond to β-agonists hold promise to improve care for asthma.

OBJECTIVE

To identify the clinical and economic circumstances under which a pharmacogenomic test that predicts response to β-agonists might or might not be an appropriate, cost-effective option.

METHODS

We synthesized published data on clinical and economic outcomes in adults 18-35 to project 10-year costs, quality-adjusted life years and cost-effectiveness of pharmacogenomic testing for β-agonist response.

RESULTS

Pharmacogenomic testing for β-agonist response conferred a cost-effectiveness ratio of $13,700 per quality-adjusted life year gained compared with no testing.

CONCLUSION

Pharmacogenomic testing for β-agonist response in individuals with asthma is potentially cost effective and should be pursued by test developers.

Abbreviation
Per Med
Publication Date
2015-11-19
Volume
12
Issue
6
Page Numbers
574-584
Pubmed ID
29750604
Medium
Print
Full Title
Pharmacogenomic test that predicts response to β-agonists in adults with asthma is cost effective.
Authors
Wu AC, Gay C, Rett MD, Fuhlbrigge AL